Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group.
J Card Fail 1995; 1(2):101-7JC

Abstract

Seventy-nine patients with stable chronic congestive heart failure were randomized into a double-blind, crossover placebo controlled study with 3-month treatment periods, where either 100 mg coenzyme Q10 (CoQ10) or placebo was added to conventional therapy. Mean patient age was 61 +/- 10 years, ejection fraction at rest was 22% +/- 10%, and maximal exercise tolerance was 91 +/- 30 W. The follow-up examinations included ejection fraction (primary objective), exercise test, and quality of life questions. Ejection fraction at rest, during a slight volume load, and during a submaximal supine exercise increased slightly compared with placebo: 24% +/- 12% versus 23% +/- 12% (NS), 25% +/- 13% versus 23% +/- 12% (P < .05), and 23% +/- 11% versus 22% +/- 11% (NS). Maximal exercise capacity increased from 94 +/- 31 W during the placebo period to 100 +/- 34 W during the CoQ10 period (P < .05). Total score for the quality of life assessment increased significantly from 107 +/- 23 during the placebo period to 113 +/- 22 during the CoQ10 period (P < .05). The results indicate that oral long-term treatment with 100 mg CoQ10 in patients with congestive heart failure only slightly improves maximal exercise capacity and the quality of life and that the clinical importance of this needs to be further evaluated.

Authors+Show Affiliations

Department of Cardiology, Karolinska Hospital, Stockholm, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9420639

Citation

Hofman-Bang, C, et al. "Coenzyme Q10 as an Adjunctive in the Treatment of Chronic Congestive Heart Failure. the Q10 Study Group." Journal of Cardiac Failure, vol. 1, no. 2, 1995, pp. 101-7.
Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J Card Fail. 1995;1(2):101-7.
Hofman-Bang, C., Rehnqvist, N., Swedberg, K., Wiklund, I., & Aström, H. (1995). Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. Journal of Cardiac Failure, 1(2), pp. 101-7.
Hofman-Bang C, et al. Coenzyme Q10 as an Adjunctive in the Treatment of Chronic Congestive Heart Failure. the Q10 Study Group. J Card Fail. 1995;1(2):101-7. PubMed PMID: 9420639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. AU - Hofman-Bang,C, AU - Rehnqvist,N, AU - Swedberg,K, AU - Wiklund,I, AU - Aström,H, PY - 1995/3/1/pubmed PY - 1998/1/8/medline PY - 1995/3/1/entrez SP - 101 EP - 7 JF - Journal of cardiac failure JO - J. Card. Fail. VL - 1 IS - 2 N2 - Seventy-nine patients with stable chronic congestive heart failure were randomized into a double-blind, crossover placebo controlled study with 3-month treatment periods, where either 100 mg coenzyme Q10 (CoQ10) or placebo was added to conventional therapy. Mean patient age was 61 +/- 10 years, ejection fraction at rest was 22% +/- 10%, and maximal exercise tolerance was 91 +/- 30 W. The follow-up examinations included ejection fraction (primary objective), exercise test, and quality of life questions. Ejection fraction at rest, during a slight volume load, and during a submaximal supine exercise increased slightly compared with placebo: 24% +/- 12% versus 23% +/- 12% (NS), 25% +/- 13% versus 23% +/- 12% (P < .05), and 23% +/- 11% versus 22% +/- 11% (NS). Maximal exercise capacity increased from 94 +/- 31 W during the placebo period to 100 +/- 34 W during the CoQ10 period (P < .05). Total score for the quality of life assessment increased significantly from 107 +/- 23 during the placebo period to 113 +/- 22 during the CoQ10 period (P < .05). The results indicate that oral long-term treatment with 100 mg CoQ10 in patients with congestive heart failure only slightly improves maximal exercise capacity and the quality of life and that the clinical importance of this needs to be further evaluated. SN - 1071-9164 UR - https://www.unboundmedicine.com/medline/citation/9420639/Coenzyme_Q10_as_an_adjunctive_in_the_treatment_of_chronic_congestive_heart_failure__The_Q10_Study_Group_ L2 - https://medlineplus.gov/heartfailure.html DB - PRIME DP - Unbound Medicine ER -